Skip to main content

Advertisement

Table 1 Clinical and serological features of patients by study group

From: Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study

Characteristics Rhupus RA SLE Controls
Number of patients 7 7 7 7
Median age, years (range) 44 (25–64) 46 (31–61) 41 (24–66) 41 (28–63)
Median age of onset, years (range) 26 (11–61) 40 (27–45) 39 (18–52) -
SLE criteria, n (percentage)     
   Malar rash 5 (71) - 7 (100) -
   Discoid lupus 1 (14) - 1 (14) -
   Photosensitivity 4 (57) - 5 (71) -
   Oral ulcers 5 (71) - 5 (71) -
   Serositis 3 (43) - 0 (0) -
   Renal 2 (29) - 2 (29) -
   Neurological 1 (14) - 1 (14) -
   Hematological 7 (100) - 6 (86) -
   Immunological 4 (57) - 5 (71) -
   ANA 7 (100) - 7 (100) -
RA criteria, n (percentage)     
   Morning stiffness 3 (43) 5 (71) - -
   Arthritis in more than three areas 7 (100) 7 (100) - -
   Arthritis of hands 7 (100) 7 (100) - -
   Symmetric arthritis 7 (100) 7 (100) - -
   Rheumatoid nodules 0 (0) 3 (43) - -
   RF 5 (71) 6 (86) - -
   X-ray changes 7 (100) 7 (100) - -
Serology, n (percentage)     
   Anti-CCP 4 (57) 6 (86) 0 (0) 0 (0)
   ANA 7 (100) 0 (0) 7 (100) 2 (29)
   Anti-dsDNA 4 (57) 0 (0) 4 (57) 0 (0)
   Anti-SSA 4 (57) 0 (0) 3 (43) 1 (14)
   Anti-SSB 1 (14) 0 (0) 1 (14) 0 (0)
   Anti-Sm 1 (14) 0 (0) 2 (29) 0 (0)
   Anti-RNP 1 (14) 0 (0) 2 (29) 0 (0)
   RF 5 (71) 6 (86) 2 (29) 1 (14)
  1. ANA, antinuclear antibodies; anti-CCP, antibodies against cyclic citrullinated peptides; anti-dsDNA, antibodies against double-stranded DNA; anti-RNP, antibodies against ribonucleoprotein; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome.